 |
|
|
|
This month we would like to know...
Egrifta (tesamorelin) was recently FDA-approved to treat HIV-associated lipodystrophy (aka, visceral adipose tissue [VAT]), which will be available in January 2011. VAT has been associated with adverse cardiovascular outcomes. How is your health-system covering or planning on covering this injectable drug product?
| 1) |
We will be/are covering it as a medically necessary drug if patient's meet criteria for use. |
| |
|
| 2) |
We will be/are covering it as a medically necessary drug for all HIV patients. |
| |
|
| 3) |
We will not be covering it at all since it is a cosmetic product. |
| |
|
| 4) |
We have not yet decided how to cover this product. |
| |
|
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
More reduction in LDL cholesterol lessens vascular events
Further reductions in LDL cholesterol with more intensive statin regimens safely produce definite further reductions in vascular events, even down to very low LDL levels, lower than current targets, according to the results of 2 meta-analyses, as reported Nov. 8 online by The Lancet. More... |
|
| |
CCCS program linked to lower healthcare costs in CAD patients
Among patients with coronary artery disease (CAD), participating in a secondary prevention program featuring a clinical pharmacy specialist and registered nurse is associated with lower healthcare expenditures, according to research published in the November issue of Pharmacotherapy, HealthDay News reported. More... |
|
|
| |
| |
| THERAPY UPDATE |
Nonanthracycline regimens for adjuvant treatment of operable breast cancer
Nonanthracycline-containing chemotherapy regimens for the adjuvant treatment of operable stage I to III breast cancer are discussed, including efficacy and toxicity results from recent randomized clinical trials comparing anthracycline to nonanthracycline-containing regimens. More... |
Top 5 Web Stories:
Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia
Attention deficit hyperactivity disorder: More than a child's disease
FDA Actions in Brief November 2010 (Latuda, Ofirmev, Cymbalta, Botox, Pradaxa, Afinitor, Teflaro, Herceptin, Kapvay)
Olmesartan medoxomil, amlodipine, and hydrochlorothiazide (Tribenzor): A new 3-drug combination product for the treatment of hypertension
FDA Pipeline Preview, November 2010 (Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol extended-release oral analgesic, AVP-21D9, 1% tenofovir vaginal gel, AFM 13, hGH-CTP, Rozrolimupab, Nefecon, SB1518 JAK2 inhibitor)
|
|
|
|
|
|
| |
